Famar and Roche have signed an agreement for the acquisition by Famar of Roche’s Leganes, Spain site. In addition, the two companies have signed a long-term manufacturing agreement that will allow Famar Leganes to supply Roche in the future from this facility with the current portfolio of products produced at the site. The transfer of full ownership of the Leganes site is expected to be completed July 1, 2016.

Famar is a contract manufacturing organization (CMO) with a network of 11 manufacturing sites in Europe, which supply a wide range to the industry, serving most international markets.

The Leganes site is modern, well equipped and is approved for worldwide supply. It provides Famar with capacities and expertise in the production of solid dosage forms with high-potency active pharmaceutical ingredients, which represents new technology for the company and adds to Famar’s technology portfolio in solid dosage formulations.

Because the Leganes site is FDA certified, it will give Famar access to the U.S. market, which Famar anticipates will help to accelerate growth. By early 2017, Famar is expected to have two FDA approved sites in their global network, the other one is based in Canada.